Vimab Group (VIMAB) 주식 개요Vimab Group AB(publ)는 스웨덴 및 국제적으로 에너지 서비스, 산업 및 환경 기술 분야의 경영 컨설팅 활동을 하고 있습니다. 자세히 보기VIMAB 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성3/6배당0/6위험 분석의미 있는 시가총액이 없습니다(SEK77M)지난 5년간 매년 수익이 32.6% 감소했습니다.지난 3개월 동안 주가 변동성이 Swedish 시장과 비교했을 때 매우 높았습니다.cash runway 경력이 1년 미만입니다.모든 위험 점검 보기VIMAB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 2.9082.3% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-102m524m2016201920222025202620282031Revenue SEK 524.2mEarnings SEK 40.3mAdvancedSet Fair ValueView all narrativesVimab Group AB (publ) 경쟁사Front VenturesSymbol: NGM:FRNT BMarket cap: SEK 108.2mNovus Group InternationalSymbol: NGM:NOVUMarket cap: SEK 35.1mHultstrom GroupSymbol: OM:HULT BMarket cap: SEK 226.9mSibekSymbol: OM:SIBEKMarket cap: SEK 476.2m가격 이력 및 성과Vimab Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가SEK 2.9052주 최고가SEK 8.7052주 최저가SEK 1.79베타-1.451개월 변동11.54%3개월 변동12.40%1년 변동-61.94%3년 변동-68.13%5년 변동n/aIPO 이후 변동-71.00%최근 뉴스 및 업데이트Reported Earnings • Mar 17Full year 2025 earnings released: kr3.90 loss per share (vs kr3.31 loss in FY 2024)Full year 2025 results: kr3.90 loss per share (further deteriorated from kr3.31 loss in FY 2024). Revenue: kr328.6m (up 1.0% from FY 2024). Net loss: kr101.7m (loss widened 32% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 41% per year.분석 기사 • Jan 14Investors Give Vimab Group AB (publ) (STO:VIMAB) Shares A 26% HidingTo the annoyance of some shareholders, Vimab Group AB (publ) ( STO:VIMAB ) shares are down a considerable 26% in the...New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.5m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (kr89.5m market cap, or US$9.74m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).공지 • Dec 03Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,545,158 Price\Range: SEK 4.8 Transaction Features: Rights OfferingNew Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (kr110.4m market cap, or US$11.7m).Reported Earnings • Nov 10Third quarter 2025 earnings released: kr0.20 loss per share (vs kr0.49 loss in 3Q 2024)Third quarter 2025 results: kr0.20 loss per share (improved from kr0.49 loss in 3Q 2024). Revenue: kr94.4m (up 24% from 3Q 2024). Net loss: kr5.03m (loss narrowed 57% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.더 많은 업데이트 보기Recent updatesReported Earnings • Mar 17Full year 2025 earnings released: kr3.90 loss per share (vs kr3.31 loss in FY 2024)Full year 2025 results: kr3.90 loss per share (further deteriorated from kr3.31 loss in FY 2024). Revenue: kr328.6m (up 1.0% from FY 2024). Net loss: kr101.7m (loss widened 32% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 41% per year.분석 기사 • Jan 14Investors Give Vimab Group AB (publ) (STO:VIMAB) Shares A 26% HidingTo the annoyance of some shareholders, Vimab Group AB (publ) ( STO:VIMAB ) shares are down a considerable 26% in the...New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.5m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (kr89.5m market cap, or US$9.74m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).공지 • Dec 03Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,545,158 Price\Range: SEK 4.8 Transaction Features: Rights OfferingNew Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (kr110.4m market cap, or US$11.7m).Reported Earnings • Nov 10Third quarter 2025 earnings released: kr0.20 loss per share (vs kr0.49 loss in 3Q 2024)Third quarter 2025 results: kr0.20 loss per share (improved from kr0.49 loss in 3Q 2024). Revenue: kr94.4m (up 24% from 3Q 2024). Net loss: kr5.03m (loss narrowed 57% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.분석 기사 • Sep 10It's A Story Of Risk Vs Reward With Vimab Group AB (publ) (STO:VIMAB)With a median price-to-sales (or "P/S") ratio of close to 0.6x in the Professional Services industry in Sweden, you...Reported Earnings • Aug 31Second quarter 2025 earnings released: kr0.40 loss per share (vs kr0.16 loss in 2Q 2024)Second quarter 2025 results: kr0.40 loss per share (further deteriorated from kr0.16 loss in 2Q 2024). Revenue: kr84.6m (down 12% from 2Q 2024). Net loss: kr11.2m (loss widened 208% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year.New Risk • Jun 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.8m free cash flow). Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (kr211.3m market cap, or US$21.9m).Reported Earnings • May 22First quarter 2025 earnings released: kr1.20 loss per share (vs kr0.80 loss in 1Q 2024)First quarter 2025 results: kr1.20 loss per share (further deteriorated from kr0.80 loss in 1Q 2024). Revenue: kr56.7m (down 16% from 1Q 2024). Net loss: kr30.9m (loss widened 72% from 1Q 2024).공지 • May 14Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Location: at wigge & partners advokat kb`s premises, at birger jarlsgatan 25, stockholm SwedenReported Earnings • Mar 13Full year 2024 earnings released: kr3.60 loss per share (vs kr0.20 loss in FY 2023)Full year 2024 results: kr3.60 loss per share (further deteriorated from kr0.20 loss in FY 2023). Revenue: kr330.2m (down 3.5% from FY 2023). Net loss: kr76.9m (loss widened kr72.7m from FY 2023).New Risk • Mar 13New major risk - Revenue and earnings growthEarnings have declined by 2.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr173.3m market cap, or US$17.0m).분석 기사 • Feb 16Take Care Before Jumping Onto Vimab Group AB (publ) (STO:VIMAB) Even Though It's 26% CheaperVimab Group AB (publ) ( STO:VIMAB ) shares have retraced a considerable 26% in the last month, reversing a fair amount...분석 기사 • Dec 22Vimab Group AB (publ) (STO:VIMAB) Soars 29% But It's A Story Of Risk Vs RewardVimab Group AB (publ) ( STO:VIMAB ) shares have had a really impressive month, gaining 29% after a shaky period...공지 • Dec 21An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million.An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million on December 19, 2024. The divestment is intended to take place for a purchase price of approximately SEK 200 million on a cash and debt-free basis, which will be paid in cash when the shares are acquired. Net sales for Vimab AB in the financial year 2023 amounted to approximately SEK 200.1 million with an EBITDA result of approximately SEK 23.1 million, which corresponds to an EBITDA margin of approximately 11.5 percent. The divestiture is conditional on the Stakeholder's due diligence and the parties agreeing to enter into a share transfer agreement. Signing of the share transfer agreement and access is planned for the first quarter of 2025. Mangold Fondkommission AB acted as financial advisor for Vimab Group AB. Wigge & Partners Advokat Kb acted as legal advisor for Vimab Group AB.분석 기사 • Nov 06Vimab Group AB (publ)'s (STO:VIMAB) Shares Not Telling The Full StoryThere wouldn't be many who think Vimab Group AB (publ)'s ( STO:VIMAB ) price-to-sales (or "P/S") ratio of 0.7x is worth...New Risk • Nov 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (kr259.6m market cap, or US$24.2m).Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023).Reported Earnings • May 09First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023)First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023).공지 • May 08Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024, at 10:00 W. Europe Standard Time. Location: wigge & partners advokat kb`s, premises at birger jarlsgatan 25, stockholm Sweden분석 기사 • Mar 14We Think Vimab Group (STO:VIMAB) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Mar 13Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022).Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.주주 수익률VIMABSE Professional ServicesSE 시장7D-3.0%1.7%3.7%1Y-61.9%-30.9%15.7%전체 주주 수익률 보기수익률 대 산업: VIMAB은 지난 1년 동안 -30.9%의 수익을 기록한 Swedish Professional Services 산업보다 저조한 성과를 냈습니다.수익률 대 시장: VIMAB은 지난 1년 동안 15.7%를 기록한 Swedish 시장보다 저조한 성과를 냈습니다.주가 변동성Is VIMAB's price volatile compared to industry and market?VIMAB volatilityVIMAB Average Weekly Movement23.7%Professional Services Industry Average Movement8.9%Market Average Movement6.5%10% most volatile stocks in SE Market13.1%10% least volatile stocks in SE Market3.7%안정적인 주가: VIMAB의 주가는 지난 3개월 동안 Swedish 시장보다 변동성이 컸습니다.시간에 따른 변동성: VIMAB의 주간 변동성은 지난 1년간 13%에서 24%로 증가했습니다.회사 소개설립직원 수CEO웹사이트2011171Peter Fredellvimabgroup.comVimab Group AB(publ)는 스웨덴 및 국제적으로 에너지 서비스, 산업 및 환경 기술 분야의 경영 컨설팅 활동을 하고 있습니다. 이 회사는 2011년에 설립되었으며 스웨덴 모탈라에 본사를 두고 있습니다.더 보기Vimab Group AB (publ) 기초 지표 요약Vimab Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?VIMAB 기초 통계시가총액SEK 76.98m순이익 (TTM)-SEK 101.68m매출 (TTM)SEK 318.19m0.2x주가매출비율(P/S)-0.8x주가수익비율(P/E)VIMAB는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표VIMAB 손익계산서 (TTM)매출SEK 318.19m매출원가SEK 269.44m총이익SEK 48.75m기타 비용SEK 150.42m순이익-SEK 101.68m최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-3.83총이익률15.32%순이익률-31.96%부채/자본 비율243.1%VIMAB의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/07 11:04종가2026/05/07 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vimab Group AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 17Full year 2025 earnings released: kr3.90 loss per share (vs kr3.31 loss in FY 2024)Full year 2025 results: kr3.90 loss per share (further deteriorated from kr3.31 loss in FY 2024). Revenue: kr328.6m (up 1.0% from FY 2024). Net loss: kr101.7m (loss widened 32% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 41% per year.
분석 기사 • Jan 14Investors Give Vimab Group AB (publ) (STO:VIMAB) Shares A 26% HidingTo the annoyance of some shareholders, Vimab Group AB (publ) ( STO:VIMAB ) shares are down a considerable 26% in the...
New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.5m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (kr89.5m market cap, or US$9.74m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).
공지 • Dec 03Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,545,158 Price\Range: SEK 4.8 Transaction Features: Rights Offering
New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (kr110.4m market cap, or US$11.7m).
Reported Earnings • Nov 10Third quarter 2025 earnings released: kr0.20 loss per share (vs kr0.49 loss in 3Q 2024)Third quarter 2025 results: kr0.20 loss per share (improved from kr0.49 loss in 3Q 2024). Revenue: kr94.4m (up 24% from 3Q 2024). Net loss: kr5.03m (loss narrowed 57% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.
Reported Earnings • Mar 17Full year 2025 earnings released: kr3.90 loss per share (vs kr3.31 loss in FY 2024)Full year 2025 results: kr3.90 loss per share (further deteriorated from kr3.31 loss in FY 2024). Revenue: kr328.6m (up 1.0% from FY 2024). Net loss: kr101.7m (loss widened 32% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 41% per year.
분석 기사 • Jan 14Investors Give Vimab Group AB (publ) (STO:VIMAB) Shares A 26% HidingTo the annoyance of some shareholders, Vimab Group AB (publ) ( STO:VIMAB ) shares are down a considerable 26% in the...
New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.5m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (kr89.5m market cap, or US$9.74m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).
공지 • Dec 03Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,545,158 Price\Range: SEK 4.8 Transaction Features: Rights Offering
New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (kr110.4m market cap, or US$11.7m).
Reported Earnings • Nov 10Third quarter 2025 earnings released: kr0.20 loss per share (vs kr0.49 loss in 3Q 2024)Third quarter 2025 results: kr0.20 loss per share (improved from kr0.49 loss in 3Q 2024). Revenue: kr94.4m (up 24% from 3Q 2024). Net loss: kr5.03m (loss narrowed 57% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.
분석 기사 • Sep 10It's A Story Of Risk Vs Reward With Vimab Group AB (publ) (STO:VIMAB)With a median price-to-sales (or "P/S") ratio of close to 0.6x in the Professional Services industry in Sweden, you...
Reported Earnings • Aug 31Second quarter 2025 earnings released: kr0.40 loss per share (vs kr0.16 loss in 2Q 2024)Second quarter 2025 results: kr0.40 loss per share (further deteriorated from kr0.16 loss in 2Q 2024). Revenue: kr84.6m (down 12% from 2Q 2024). Net loss: kr11.2m (loss widened 208% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year.
New Risk • Jun 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.8m free cash flow). Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (kr211.3m market cap, or US$21.9m).
Reported Earnings • May 22First quarter 2025 earnings released: kr1.20 loss per share (vs kr0.80 loss in 1Q 2024)First quarter 2025 results: kr1.20 loss per share (further deteriorated from kr0.80 loss in 1Q 2024). Revenue: kr56.7m (down 16% from 1Q 2024). Net loss: kr30.9m (loss widened 72% from 1Q 2024).
공지 • May 14Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Location: at wigge & partners advokat kb`s premises, at birger jarlsgatan 25, stockholm Sweden
Reported Earnings • Mar 13Full year 2024 earnings released: kr3.60 loss per share (vs kr0.20 loss in FY 2023)Full year 2024 results: kr3.60 loss per share (further deteriorated from kr0.20 loss in FY 2023). Revenue: kr330.2m (down 3.5% from FY 2023). Net loss: kr76.9m (loss widened kr72.7m from FY 2023).
New Risk • Mar 13New major risk - Revenue and earnings growthEarnings have declined by 2.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr173.3m market cap, or US$17.0m).
분석 기사 • Feb 16Take Care Before Jumping Onto Vimab Group AB (publ) (STO:VIMAB) Even Though It's 26% CheaperVimab Group AB (publ) ( STO:VIMAB ) shares have retraced a considerable 26% in the last month, reversing a fair amount...
분석 기사 • Dec 22Vimab Group AB (publ) (STO:VIMAB) Soars 29% But It's A Story Of Risk Vs RewardVimab Group AB (publ) ( STO:VIMAB ) shares have had a really impressive month, gaining 29% after a shaky period...
공지 • Dec 21An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million.An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million on December 19, 2024. The divestment is intended to take place for a purchase price of approximately SEK 200 million on a cash and debt-free basis, which will be paid in cash when the shares are acquired. Net sales for Vimab AB in the financial year 2023 amounted to approximately SEK 200.1 million with an EBITDA result of approximately SEK 23.1 million, which corresponds to an EBITDA margin of approximately 11.5 percent. The divestiture is conditional on the Stakeholder's due diligence and the parties agreeing to enter into a share transfer agreement. Signing of the share transfer agreement and access is planned for the first quarter of 2025. Mangold Fondkommission AB acted as financial advisor for Vimab Group AB. Wigge & Partners Advokat Kb acted as legal advisor for Vimab Group AB.
분석 기사 • Nov 06Vimab Group AB (publ)'s (STO:VIMAB) Shares Not Telling The Full StoryThere wouldn't be many who think Vimab Group AB (publ)'s ( STO:VIMAB ) price-to-sales (or "P/S") ratio of 0.7x is worth...
New Risk • Nov 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (kr259.6m market cap, or US$24.2m).
Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023).
Reported Earnings • May 09First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023)First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023).
공지 • May 08Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024, at 10:00 W. Europe Standard Time. Location: wigge & partners advokat kb`s, premises at birger jarlsgatan 25, stockholm Sweden
분석 기사 • Mar 14We Think Vimab Group (STO:VIMAB) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Mar 13Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022).
Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.
